Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood (2025) 146 (24): 2902–2913.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Journal Articles

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Omar Siddiqi, Shikun Wang, Margaret Doyle, Sanjay Vara, Benjamin Schroeder, Jordan Schecter, Catherine Higgins, Renee Smith, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2025-2197

Published: 2025

Journal Articles

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Blood (2025) 146 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2025-4014

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Aarif Ahsan, Adam Luo, Cesar Rodriguez Valdes, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Thomas Doerr, Rajvineeth Kumar Pothacamury, Chetasi Talati, Brenda Chyla, Jeremy Ross

Blood (2025) 146 (Supplement 1): 5813.

https://doi.org/10.1182/blood-2025-5813

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Long-term follow-up of venetoclax therapy in AL amyloidosis

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Michael Hughes, Michaela Liedtke, Jeffrey Zonder, Mansen Yu, Anita D'Souza

Blood (2025) 146 (Supplement 1): 7497.

https://doi.org/10.1182/blood-2025-7497

Published: 2025

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

Bayesian machine learning, medical history, and predictive models for early diagnosis of systemic light chain amyloidosis

Anita D'Souza, Liliana Pezzin, Noel Estrada-Merly, Rodney Sparapani

Blood (2025) 146 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2025-3967

Published: 2025

Journal Articles

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Blood (2025) 146 (Supplement 1): 247.

https://doi.org/10.1182/blood-2025-247

Published: 2025

Journal Articles

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Khanmi Kasomva, Kirthi Pulakanti, Josiah Murray, Kritika Yadav, Ravi Narra, Marcelo Pasquini, Anita D'Souza, Meera Mohan, Othman Akhtar, Deepak Parashar, Fumou Sun, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood (2025) 146 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2025-5716

Published: 2025

Journal Articles

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

Frederick Shi, Xinyi Yang, Juan Li, Shijing Wang, Bin Sun, Jing Dong, Peiman Hematti, Siegfried Janz, Anita D'Souza, Laura Michaelis, Binod Dhakal, Fumou Sun

Blood (2025) 146 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2025-5715

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Long-term follow-up of venetoclax therapy in AL amyloidosis

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Bayesian machine learning, medical history, and predictive models for early diagnosis of systemic light chain amyloidosis

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only